Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 278, Issue 16, Pages 14013-14019Publisher
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M209702200
Keywords
-
Categories
Funding
- NCI NIH HHS [K01 CA098809, R01 CA089212, R01CA89212] Funding Source: Medline
- NHLBI NIH HHS [T32-HL007821] Funding Source: Medline
Ask authors/readers for more resources
Hypoxia-inducible factors (HIF) are a family of heterodimeric transcriptional regulators that play pivotal roles in the regulation of cellular utilization of oxygen and glucose and are essential transcriptional regulators of angiogenesis in solid tumor and ischemic disorders. The transactivation activity of HIF complexes requires the recruitment of p300/CREB-binding protein (CBP) by HIF-1alpha and HIF-2alpha that undergo oxygen-dependent degradation. HIF activation in tumors is caused by several factors including mitogen-activated protein kinase (MAPK) signaling. Here we investigated the molecular basis for HIF activation by MAPK. We show that MAPK is required for the transactivation activity of HIF-1alpha. Furthermore, inhibition of MAPK disrupts the HIF-p300 interaction and suppresses the transactivation activity of p300. Overexpression of MEK1, an upstream MAPK activator, stimulates the transactivation of both p300 and HIF-1alpha. Interestingly, the C-terminal transactivation domain of HIF-1alpha is not a direct substrate of MAPK, and HIF-1alpha phosphorylation is not required for HIFCAD/p300 interaction. Taken together, our data suggest that MAPK signaling facilitates HIF activation through p300/CBP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available